Holen Sie sich die Stockscreener-App
6.77
6.49%
-0.47
Handel nachbörslich:
6.76
-0.010
-0.15%
Schlusskurs vom Vortag:
$7.24
Offen:
$7.11
24-Stunden-Volumen:
632.34K
Relative Volume:
0.57
Marktkapitalisierung:
$494.12M
Einnahmen:
$531.00K
Nettoeinkommen (Verlust:
$-104.97M
KGV:
-2.5058
EPS:
-2.7017
Netto-Cashflow:
$-107.19M
1W Leistung:
-1.88%
1M Leistung:
-1.74%
6M Leistung:
+34.86%
1J Leistung:
+149.82%
1-Tages-Spanne:
$6.66
$7.11
1-Wochen-Bereich:
$6.66
$7.44
52-Wochen-Spanne:
$1.45
$10.99
Lexeo Therapeutics Inc Stock (LXEO) Company Profile
Firmenname
Lexeo Therapeutics Inc
Sektor
Branche
Telefon
(212) 547-9879
Adresse
345 PARK AVENUE SOUTH, NEW YORK
Compare LXEO vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LXEO
Lexeo Therapeutics Inc
|
6.77 | 528.43M | 531.00K | -104.97M | -107.19M | -2.7017 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.14 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Lexeo Therapeutics Inc Stock (LXEO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-18 | Eingeleitet | Raymond James | Strong Buy |
| 2025-11-20 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-10-15 | Eingeleitet | Guggenheim | Buy |
| 2025-07-31 | Eingeleitet | Oppenheimer | Outperform |
| 2024-06-13 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-06-06 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-11-28 | Eingeleitet | Chardan Capital Markets | Buy |
| 2023-11-28 | Eingeleitet | JP Morgan | Overweight |
| 2023-11-28 | Eingeleitet | Leerink Partners | Outperform |
| 2023-11-28 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-11-28 | Eingeleitet | Stifel | Buy |
Alle ansehen
Lexeo Therapeutics Inc Aktie (LXEO) Neueste Nachrichten
Lexeo Therapeutics to Participate in the Leerink Global Healthcare Conference - The Manila Times
Nasdaq Moves: Can Lexeo Therapeutics Inc ride the EV waveRate Cut & Safe Capital Growth Trade Ideas - baoquankhu1.vn
Lexeo Therapeutics Highlights FA and PKP2 Cardiac Gene Therapy Progress at Oppenheimer Conference - MarketBeat
LXEO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Earnings Update: Is Lexeo Therapeutics Inc forming a bullish divergenceProduct Launch & Consistent Profit Focused Trading Strategies - baoquankhu1.vn
Profit Review: Is Lexeo Therapeutics Inc forming a bullish divergenceShare Buyback & Risk Controlled Stock Alerts - baoquankhu1.vn
Narinder Pal Bhalla Net Worth (2026) - GuruFocus
Insider Selling: Lexeo Therapeutics (NASDAQ:LXEO) CEO Sells $64,903.74 in Stock - Defense World
Lexeo Therapeutics (NASDAQ:LXEO) COO Sells $19,302.40 in Stock - Defense World
Aug Macro: Is Massimo Group gaining market shareMarket Trend Report & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
Will Lexeo Therapeutics Inc. outperform its industry peersEarnings Risk Summary & Capital Efficient Trade Techniques - mfd.ru
Balyasny Asset Management L.P. Increases Stake in Lexeo Therapeu - GuruFocus
Top Brass at Biotech Player Quietly Cash Out in Latest Insider Move - TipRanks
Balyasny Asset Management L.P. Increases Stake in Lexeo Therapeutics Inc. - GuruFocus
LXEO (NASDAQ: LXEO) affiliate plans sale of 4,867 vested shares - Stock Titan
LXEO Should I Buy - Intellectia AI
Citadel discloses 7.4% Lexeo Therapeutics (LXEO) ownership in 13G/A - Stock Titan
BioAgilytix Labs, Inc Receives FDA Breakthrough Device Designation for Anti-AAV Antibody Assay - The Courier-Journal
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Published on: 2026-02-16 16:57:11 - baoquankhu1.vn
Is Lexeo Therapeutics Inc. still a buy after recent gainsJuly 2025 Earnings & Fast Entry Momentum Trade Alerts - mfd.ru
Lexeo Therapeutics Details FDA Path for LX2006, Highlights LVMI Gains at Guggenheim Biotech Summit - MarketBeat
A | Does Lexeo Therapeutics, Inc. have declining or rising EPSPortfolio Update Report & Weekly Watchlist of Top Performers - mfd.ru
Page not foundAirwhon - MarketBeat
Lexeo Therapeutics (NASDAQ:LXEO) Stock Price Down 3.2%Time to Sell? - MarketBeat
Will Lexeo Therapeutics Inc. announce a stock splitJuly 2025 Spike Watch & Smart Allocation Stock Reports - mfd.ru
Volatility Watch: Is Lexeo Therapeutics Inc backed by strong institutional buyingPortfolio Return Report & Low Risk High Reward Ideas - baoquankhu1.vn
Lexeo Therapeutics Announces Head of Research Transition - The Globe and Mail
Lexeo Therapeutics (LXEO) CFO receives RSUs and 226,665-share stock option - Stock Titan
Lexeo Therapeutics to Participate in Upcoming Investor Conferences in February - 富途牛牛
H.C. Wainwright Says Market Remains Unconvinced on Lexeo Therapeutics, Inc. (LXEO)’s PKP2 Program - Yahoo Finance
H.C. Wainwright Says Market Remains Unconvinced on Lexeo Therapeutics, Inc. (LXEO)'s PKP2 Program - Finviz
Lexeo TherapeuticsRevolutionizing Heart Health With Gene Therapies - RTTNews
Lexeo Therapeutics Announces Key Executive Leadership Changes - The Globe and Mail
Lexeo Therapeutics Announces Key Leadership Appointments - citybiz
Lexeo Therapeutics appoints new COO and CMO, announces executive transition - Investing.com Nigeria
Lexeo Therapeutics appoints new COO and CMO, announces executive transition By Investing.com - Investing.com South Africa
Lexeo Therapeutics Announces Executive Appointments - marketscreener.com
Lexeo Therapeutics Announces Key Executive Appointments - TradingView
Lexeo Therapeutics announces key leadership appointments By Investing.com - Investing.com Canada
Lexeo appoints Jose Manuel Otero as COO - TipRanks
Lexeo Therapeutics announces key leadership appointments - Investing.com
Lexeo Therapeutics Announces Key Leadership Appointments Strengthening Cardiovascular Expertise Alongside Updates to Strategic Partnership for Novel Cardiac RNA Therapeutics - The Manila Times
Lexeo Therapeutics Announces Key Leadership Appointments to Drive Advances in Cardiovascular Medicine - Quiver Quantitative
New cardiology leaders join Lexeo as it backs novel cardiac RNA startup - stocktitan.net
Investor Mood: Can Lexeo Therapeutics Inc be the next market leaderJuly 2025 Snapshot & AI Powered Market Entry Ideas - baoquankhu1.vn
Finanzdaten der Lexeo Therapeutics Inc-Aktie (LXEO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Lexeo Therapeutics Inc-Aktie (LXEO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Townsend Richard Nolan | Chief Executive Officer |
Feb 18 '26 |
Sale |
6.38 |
10,173 |
64,924 |
392,483 |
3.69%
0.71%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):